Novo Nordisk ... trial, and in phase 1b testing showed an encouraging safety profile, as well as early signs of functional cardiac benefits, including a reduction in the heart failure biomarker ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...

(Bloomberg) -- Wegovy, the blockbuster weight-loss medication from Novo Nordisk A/S, eased heart failure symptoms for patients with diabetes in the latest large trial to support use of the drug to ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced promising results from the first part of its ESSENCE trial, showing that its drug semaglutide 2.4 mg significantly improves ...